These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 33806310)

  • 1. Daratumumab in the Treatment of Light-Chain (AL) Amyloidosis.
    Palladini G; Milani P; Malavasi F; Merlini G
    Cells; 2021 Mar; 10(3):. PubMed ID: 33806310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoclonal antibodies in the treatment of AL amyloidosis: co-targetting the plasma cell clone and amyloid deposits.
    Popkova T; Hajek R; Jelinek T
    Br J Haematol; 2020 Apr; 189(2):228-238. PubMed ID: 32072615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD38 and Anti-CD38 Monoclonal Antibodies in AL Amyloidosis: Targeting Plasma Cells and beyond.
    Roccatello D; Fenoglio R; Sciascia S; Naretto C; Rossi D; Ferro M; Barreca A; Malavasi F; Baldovino S
    Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32531894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daratumumab: A Review in Newly Diagnosed Systemic Light Chain Amyloidosis.
    Blair HA
    Drugs; 2022 Apr; 82(6):683-690. PubMed ID: 35416593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Daratumumab-based Regimens in Pretreated Light Chain (AL) Amyloidosis: A Systematic Review.
    Ehsan H; Rafae A; Masood A; Wahab A; Sana MK; Ansar I; Neupane K; Umar A; Ehsan A; Hashmi H
    Clin Lymphoma Myeloma Leuk; 2022 May; 22(5):e285-e292. PubMed ID: 34879994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Daratumumab for the treatment of AL amyloidosis.
    Sidiqi MH; Gertz MA
    Leuk Lymphoma; 2019 Feb; 60(2):295-301. PubMed ID: 30033840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal Antibody Therapies in Systemic Light-Chain Amyloidosis.
    Godara A; Palladini G
    Hematol Oncol Clin North Am; 2020 Dec; 34(6):1145-1159. PubMed ID: 33099430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Interest of daratumumab in refractory AL amyloidosis in a 96-year-old patient].
    Vial G; Lafargue A; Mercié P; Duffau P; Ribeiro E
    Rev Med Interne; 2022 Nov; 43(11):673-676. PubMed ID: 35934598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daratumumab plus CyBorD for patients with newly diagnosed light chain (AL) amyloidosis.
    Theodorakakou F; Dimopoulos MA; Kastritis E
    Ther Adv Hematol; 2021; 12():20406207211058334. PubMed ID: 34840708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
    Kastritis E; Palladini G; Minnema MC; Wechalekar AD; Jaccard A; Lee HC; Sanchorawala V; Gibbs S; Mollee P; Venner CP; Lu J; Schönland S; Gatt ME; Suzuki K; Kim K; Cibeira MT; Beksac M; Libby E; Valent J; Hungria V; Wong SW; Rosenzweig M; Bumma N; Huart A; Dimopoulos MA; Bhutani D; Waxman AJ; Goodman SA; Zonder JA; Lam S; Song K; Hansen T; Manier S; Roeloffzen W; Jamroziak K; Kwok F; Shimazaki C; Kim JS; Crusoe E; Ahmadi T; Tran N; Qin X; Vasey SY; Tromp B; Schecter JM; Weiss BM; Zhuang SH; Vermeulen J; Merlini G; Comenzo RL;
    N Engl J Med; 2021 Jul; 385(1):46-58. PubMed ID: 34192431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Options for Rescue Treatment of Patients with AL Amyloidosis Exposed to Upfront Daratumumab.
    Bellofiore C; Palladini G; Milani P
    Curr Oncol Rep; 2024 Sep; 26(9):1097-1103. PubMed ID: 38896184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual Monoclonal Antibody Therapy in Patients With Systemic AL Amyloidosis and Cardiac Involvement.
    Godara A; Siddiqui NS; Lee LX; Toskic D; Fogaren T; Varga C; Comenzo RL
    Clin Lymphoma Myeloma Leuk; 2020 Mar; 20(3):184-189. PubMed ID: 31983636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daratumumab for relapsed or refractory AL amyloidosis with high plasma cell burden.
    Schwotzer R; Manz MG; Pederiva S; Waibel C; Caspar C; Lerch E; Flammer AJ; Brouwers S; Seeger H; Heimgartner R; Fehr T; Rossi D; Bianchi E; Stüssi G; Ghilardi G; Gerber B
    Hematol Oncol; 2019 Dec; 37(5):595-600. PubMed ID: 31486522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantification of number of CD38 sites on bone marrow plasma cells in patients with light chain amyloidosis and smoldering multiple myeloma.
    Kriegsmann K; Dittrich T; Neuber B; Awwad MHS; Hegenbart U; Goldschmidt H; Hillengass J; Hose D; Seckinger A; Müller-Tidow C; Ho AD; Schönland S; Hundemer M
    Cytometry B Clin Cytom; 2018 Sep; 94(5):611-620. PubMed ID: 29577600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy in AL Amyloidosis.
    Zhang Y; Comenzo RL
    Curr Treat Options Oncol; 2022 Jul; 23(7):1059-1071. PubMed ID: 35635625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful Treatment of Systemic Light Chain Amyloidosis with Liver Involvement using Low-Frequency Daratumumab: A Case Report.
    Meng X; He J; Cheng F; Yan H; Zhu C; Guo X; Li Y; Cai Z; He D
    Am J Case Rep; 2024 Jan; 25():e942534. PubMed ID: 38229422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of AL amyloidosis in 2020.
    Palladini G; Milani P; Merlini G
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):363-371. PubMed ID: 33275753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Towards a novel target therapy for renal diseases related to plasma cell dyscrasias: The example of AL amyloidosis.
    Roccatello D; Fenoglio R; Baldovino S; Naretto C; Ferro M; Barreca A; Rossi D; Sciascia S
    Autoimmun Rev; 2020 Sep; 19(9):102622. PubMed ID: 32663622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-line daratumumab shows high efficacy and tolerability even in advanced AL amyloidosis: the real-world experience.
    Jeryczynski G; Antlanger M; Duca F; Binder-Rodriguez C; Reiter T; Simonitsch-Klupp I; Bonderman D; Kain R; Krauth MT; Agis H
    ESMO Open; 2021 Apr; 6(2):100065. PubMed ID: 33667762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Future Developments in Light Chain Amyloidosis Management.
    Rodriguez M; Lenihan D; Merlini G
    Am J Med; 2022 Apr; 135 Suppl 1():S53-S57. PubMed ID: 35081388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.